- 1、本文档共10页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
孟鲁司特钠联合卡介菌多糖核酸在儿科哮喘治疗中应用效果分析
孟鲁司特钠联合卡介菌多糖核酸在儿科哮喘治疗中应用效果分析
[摘要] 目的 探?孟鲁司特钠联合卡介菌多糖核酸在儿科哮喘治疗中的应用效果。方法 纳入100例为方便选择自2014年1月―2017年5月期间的儿科哮喘患儿为研究对象;根据哮喘患儿的入院时间先后次序分为两组,对照组单一采用孟鲁司特钠治疗,研究组采用孟鲁司特钠联合卡介菌多糖核酸治疗;比较分析两组哮喘患儿的临床治疗效果及改善情况。结果 对照组治疗效果(72.00%)明显低于研究组(94.00%),差异有统计学意义(P0.05);治疗后两组均有改善,而研究组改善幅度更大,差异有统计学意义(P0.05);对照组不良反应发生率(12.00%)明显高于研究组(2.00%),差异有统计学意义(P0.05)。结论 在儿科哮喘治疗中给予哮喘患儿应用孟鲁司特钠联合卡介菌多糖核酸的临床应用效果显著,值得临床推广与应用。
[关键词] 哮喘;孟鲁司特钠;卡介茵多糖核酸;临床效果;哮喘症状评分
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2018)01(a)-0128-03
Therapeutic Effect of Montelukast Combined with BCG Polysaccharide Nucleic Acid in the Treatment of Pediatric Asthma
ZHAO Xiu-fang
Pediatric Department, Tonghua Second People’s Hospital, Tonghua, Jilin Province, 134003 China
[Abstract] Objective This paper tries to investigate the efficacy of Montelukast combined with BCG polysaccharide nucleic acid in the treatment of pediatric asthma. Methods A total of 100 children with pediatric asthma were conveniently selected from January 2014 to May 2017. The patients were divided into two groups according to the order of admission of asthma. The control group was treated with montelukast sodium alone. The combination of montelukast sodium combined with BCG polysaccharide nucleic acid treatment; comparative analysis of the two groups of children with asthma clinical treatment and improvement of the situation. Results The effect of treatment of the control group (72.00%) was significantly lower than that of the study group(94.00%)difference are statistically significant(P0.05); the two groups after treatment were improved, and the study group improved more significantly, difference are statistically significant(P0.05); adverse reaction rate of the control group (12.00%) was significantly higher than that of the study group (2.00%), difference are statistically significant(P0.05). Conclusion The clinical application of Montelukast Combined with BCG polysaccharide nucleic acid in the treatment of asthma in children is significant, and it is
文档评论(0)